Stay updated with breaking news from Mark Bleackley. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL) has received approval from Bellberry Human Research Ethics Committee (‘HREC’) for the lead site, Emeritus Research, Camberwell, Victoria, for its phase 2 clinical trial.
Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) has garnered ethics approval to conduct a clinical trial for its proprietary drug, IHL-42X, aimed at treating...
Date: July 06, 2023 Public Announcement Incannex Receives Ethics Approval for...
Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL) has received approval from Bellberry Human Research Ethics Committee to commence a bioavailability/bioequivalence (‘BA/BE’) clinical trial on IHL-42X, the company’s proprietary drug prod
Incannex received ethics approval to begin a bioavailability/bioequivalence clinical trial on IHL-42X, a drug candidate to treat OSA.